- Cat. No.
- A11235
PF 573228
PF 573228 is a potent and selective inhibitor of focal adhesion kinase (FAK) (IC50 = 4 nM).
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that relays signals from integrins at focal adhesions. FAK inhibitors are used to study how this kinase regulates cell adhesion, migration, survival and proliferation. FAK is phosphorylated when cells attach to extracellular matrix proteins such as fibronectin. Elevated FAK expression and activity in many tumor types have made the kinase a frequent subject of cancer and angiogenesis research. The category includes PF 573228, PF-562271, NVP-TAE 226 and defactinib. Several, including PF-562271 and NVP-TAE 226, also inhibit the related proline-rich tyrosine kinase 2 (PYK2).
PF 573228 is a potent and selective inhibitor of focal adhesion kinase (FAK) (IC50 = 4 nM).
PF-562271 is an orally bioavailable small molecule and ATP-competitive focal adhesion kinase (FAK) inhibitor with potential antineoplastic and antiangiogenic activities.
Synonyms: TAE226
NVP-TAE226 is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2(IC50=3.5 nM); 10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.
PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively.
Synonyms: VS-6063; PF-04554878
Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.
PF 431396 is a dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively).
PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.
NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration.
Synonyms: CT-707
Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib (CT-707) exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM.
Synonyms: SR-2516
PND-1186 is a potent FAK inhibitor with IC50 of 1.5 nM.
PF-4618433 shows improved PYK2 potency, reduced p38 activity, and superior overall selectivity relative to the prototype BIRB796.
CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).
GSK2256098 is a focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities.
BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC50 of 17 nM. A PTK2 ligand for PROTAC.
PROTAC FAK degrader 1 is a selective and potent focal adhesion kinase (Fak) degrader with an IC50 of 6.5 nM, DC50 of 3 nM.
BI-3663 is a highly selective PTK2/FAK PROTAC, with cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 linked to Pomalidomide with a linker. Anti-cancer activity.
Synonyms: FAK Inhibitor 14
Y15 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth.
Synonyms: VS-6063 hydrochloride; VS6063; PF 04554878 hydrochloride; PF-04554878
Defactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel FAK inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.
PF-562271 hydrochloride is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively.
FC-11 is a highly potent PROTAC degrader targeting focal adhesion kinase (FAK), with a DC₉₀ of 1 nM. It offers a powerful tool for investigating FAK-mediated signaling pathways and holds potential for cancer research and therapeutic development.
Synonyms: Cyanidin 3-rutinoside chloride; Cyanidin 3-O-rutinoside chloride; Sambucin chloride
Keracyanin chloride is an orally active anthocyanin compound with potent antioxidant, anti-inflammatory, and hypoglycemic properties. It exerts its biological effects by inhibiting the NF-κB/FAK/MAPK signaling pathways, which are central to inflammation, cell adhesion, and metabolic regulation.
AT-533 is a potent inhibitor of heat shock protein 90 (Hsp90) and herpes simplex virus (HSV), exhibiting strong antitumor and antiviral activities. It suppresses tumor growth and angiogenesis by disrupting the HIF-1α/VEGF/VEGFR-2 signaling axis, a critical pathway in tumor vascularization and progression. Additionally, AT-533 inhibits key downstream signaling cascades, including Akt/mTOR/p70S6K, ERK1/2, and FAK pathways. In endothelial cells, specifically human umbilical vein endothelial cells (HUVECs), AT-533 effectively inhibits tube formation, cell migration, and invasion, highlighting its anti-angiogenic properties. These combined effects position AT-533 as a promising candidate for cancer therapy and angiogenesis-related disease research.
Synonyms: BI-853520; IN-10018
Ifebemtinib (BI-853520, IN-10018) is an orally active and potent inhibitor of focal adhesion kinase (FAK), with an IC50 of 1 nM against recombinant FAK. It exhibits antiproliferative activity in cancer cells and also inhibits FER and FES kinases, with IC50 values of 900 nM and 1040 nM, respectively.
GSK215 is a potent and selective PROTAC degrader targeting focal adhesion kinase (FAK) via the VHL E3 ligase. With a pDC50 of 8.4, it induces rapid and sustained degradation of FAK, leading to significant modulation of FAK levels over time. This compound demonstrates an extended pharmacokinetic/pharmacodynamic disconnect, making it a valuable tool for research applications in cancer biology and signaling pathways associated with cell adhesion and migration.
FAK Inhibitor 7 is a potent focal adhesion kinase (FAK) inhibitor with an IC50 of 3.58 nM. This compound disrupts downstream signaling pathways associated with FAK, including Src and AKT, leading to cell cycle arrest in the G0/G1 phase and promoting cytotoxic autophagy in ovarian cancer cells. Additionally, FAK Inhibitor 7 has demonstrated efficacy in inhibiting tumor metastasis and growth in preclinical ovarian cancer mouse models, making it a valuable tool for studying cancer biology and therapeutic interventions.